Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.
Effect of advanced glycation end products (AGEs) in the pathogenesis of cancer could be diminished by interaction with soluble RAGE or by reducing AGE-precursors via glyoxalase I. Glu111Ala polymorphism of glyoxalase I gene, AGEs, and sRAGE serum levels were studied in 113 breast cancer patients and in 58 controls. Higher frequency of the mutated C allele was found in patients with negative estrogen receptors and in patients in clinical stage III compared to controls (P< 0.05). The presence of the C allele could represent a negative prognostic factor; however, further studies are needed to confirm this hypothesis.
Germanová
Alexandra
A
Institute of Clinical Chemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Germanová
Anna
A
Tesarová
Petra
P
Jáchymová
Marie
M
Zvára
Karel
K
Zima
Tomás
T
Kalousová
Marta
M
D000368:Aged; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005787:Gene Frequency; D005838:Genotype; D017127:Glycation End Products, Advanced / Q000097:blood; D006801:Humans; D007791:Lactoylglutathione Lyase / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D000067759:Receptor for Advanced Glycation End Products; D011960:Receptors, Estrogen / Q000032:analysis; D011971:Receptors, Immunologic / Q000097:blood
D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011960:Receptors, Estrogen; D011971:Receptors, Immunologic; D007791:Lactoylglutathione Lyase